Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada

Clinical Infectious Diseases

Volumn 58, Issue 5, 2014, Pages 704-712

  Karris, Maile Y ^a   Beekmann, Susan E ^b   Mehta, Sanjay R ^a   Anderson, Christy M ^a   Polgreen, Philip M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Internal Medicine ^*  (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

HIV; PrEP; providers; survey

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG COMBINATION; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ORGANOPHOSPHORUS COMPOUND;

ADULT; ANALOGS AND DERIVATIVES; CANADA; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; DRUG COMBINATION; HIV INFECTIONS; HUMAN; MALE; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES; UNITED STATES; UTILIZATION;

ADULT; ANTI-HIV AGENTS; CANADA; CHEMOPREVENTION; DEOXYCYTIDINE; DISEASE TRANSMISSION, INFECTIOUS; DRUG COMBINATIONS; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; PRE-EXPOSURE PROPHYLAXIS; UNITED STATES;

EID: 84894248922     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit796     Document Type: Article

References (23)

1. Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. Perinatal HIV and its prevention: progress toward an HIV-free generation. Clin Perinatol 2010; 37:699-719, vii.
2. Kwon JA, Anderson J, Kerr CC, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS 2012; 26:2201-10.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
4. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999; 282:531-8.
5. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41:777-813.
6. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in. N Engl J Med 2012; 367:423-34.
9. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
10. Baeten JK, Lingappa E, Coombs J, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77-ra29.
11. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep 2013; 62:463-5.
12. Flash C, Krakower D, Mayer KH. The promise of antiretrovirals for HIV prevention. Curr Infect Dis Rep 2012; 14:185-93.
13. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011; 25:383.
14. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-9.
15. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-8.
16. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2012; 61:586-9.
17. Marschall J, Lane MA, Beekmann SE, Polgreen PM, Babcock HM. Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey. Int J Antimicrob Agents 2013; 41:272-7.
18. Dowell D, Polgreen PM, Beekmann SE, Workowski KA, Berman SM, Peterman TA. Dilemmas in the management of syphilis: a survey of infectious diseases experts. Clin Infect Dis 2009; 49:1526-9.
19. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012; 7:e40603.
20. Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J 2012; 105:199-206.
21. Senn H,Wilton J, Sharma M, Fowler S, Tan D. Knowledge of and opinions on HIV pre-exposure prophylaxis among front-line service providers at Canadian AIDS Service Organizations. AIDS Res Hum Retroviruses 2013; 29:1183-9.
22. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-22.
23. Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIVAIDS 2013; 8:50-8.